by Jacob Arfwedson
Institute for Policy Innovation
August 13, 2004
Policy Report
Supporters of parallel trade in pharmaceuticals argue that it lower prices, which is popular with consumers and cash-strapped governments. But, in fact, parallel trade reduces safety, since it represents an end-run around domestic inspection procedures. More importantly, reimportation undermines intellectual property protection and hence incentives to invest in research and development of IP-based products, which will have ominous implications for consumers in the long-run



Heritage FoundationInsiderOnline is a product of The Heritage Foundation.
214 Massachusetts Avenue NE | Washington DC 20002-4999
ph 202.546.4400 | fax 202.546.8328
© 1995 - 2014 The Heritage Foundation